4 results match your criteria: "Fuqua School of Business at Duke University[Affiliation]"
Quantifying the Financial Impact of Delayed Adoption of CPT Code Changes in Radiology.
Curr Probl Diagn Radiol
December 2021
Division of Interventional Radiology, Department of Radiology, Duke Health, Durham, NC. Electronic address:
Purpose: To quantify the financial effect of delayed reporting of new moderate sedation (MS) Current Procedural Terminology (CPT) codes at an academic radiology practice, and to identify barriers to timely reporting.
Materials And Methods: Billing and reimbursement data was collected for a 28-month period (January 1, 2017-April 30, 2019). Reporting of new MS codes was identified and compared to the number of procedures performed by radiology over the study period.
Despite doing well on antiretroviral therapy, many people living with HIV have expressed a willingness to accept substantial risks for an HIV cure. To date, few studies have assessed the specific quantitative maximal risk that future participants might take; probed whether, according to future participants, the risk can be offset by the benefits; and examined whether taking substantial risk is a reasonable decision. In this qualitative study, we interviewed 22 people living with HIV and used standard gamble methodology to assess the maximum chance of death a person would risk for an HIV cure.
View Article and Find Full Text PDFImplementation of a Market Entry Reward within the United States.
J Law Med Ethics
June 2018
Gregory W. Daniel, Ph.D., M.P.H., R.Ph., is the Deputy Director of the Robert J. Margolis, MD, Center for Health Policy and a Clinical Professor in the Fuqua School of Business at Duke University. He received his B.S. in Pharmacy, M.S. in Pharmaceutical Administration, and M.P.H. in Biostatistics from the Ohio State University and his Ph.D. in Pharmaceutical Economics, Policy, and Outcomes from the University of Arizona. Monika Schneider, Ph.D., is a Research Associate at the Robert J. Margolis, MD, Center for Health Policy at Duke University. She received her B.S. in Biological Sciences from Butler University and her Ph.D. in Microbiology and Immunology at the University of North Carolina, Chapel Hill. Marianne Hamilton Lopez, Ph.D., is a Research Director at the Robert J. Margolis, MD, Center for Health Policy at Duke University. She received her B.A. in Politics and Women's Studies from Earlham College, her M.P.A. from the George Washington University, and her Ph.D. in Public Policy from the University of Maryland, Baltimore County. Mark B. McClellan, M.D., Ph.D., is the Director of the Robert J. Margolis, MD, Center for Health Policy and the Robert J. Margolis, MD, Professor of Business, Medicine and Policy, with appointments as Professor of the Practice of Business Administration in the Fuqua School of Business and Professor of the Practice in the Sanford School of Public Policy at Duke University. He received his B.A. at the University of Texas, Austin, his M.P.A. from Harvard University, his M.D. from the Harvard-MIT Division of Health Sciences and Technology, and his Ph.D. from the Massachusetts Institute of Technology.
As part of a multifactorial approach to address weak incentives for innovative antimicrobial drug development, market entry rewards (MERs) are an emerging solution. Recently, the Duke-Margolis Center for Health Policy released the Priority Antimicrobial Value and Entry (PAVE) Award proposal, which combines a MER with payment reforms, transitioning from volume-based to "value-based" payments for antimicrobials. Here, the PAVE Award and similar MERs are reviewed, focusing on further refinement and avenues for implementation.
View Article and Find Full Text PDF